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T. Jonung,2 T. Nyheim1 and S. Aune11Department of Vascular Surgery, Haukeland University Hospital, 2Department of Surgical Research,
University of Bergen, 3Departments of Radiology, and 4Orthopaedic Surgery, Haukeland University Hospital,
Bergen, NorwayObjectives. To investigate the impact of clinical risk factors, plasma homocysteine and haemostatic variables on the results
after endovascular treatment of symptomatic atherosclerosis of the common iliac artery.
Design. Prospective observational study.
Setting. University hospital.
Patients and method. The study included 139 technically successful interventions in 103 patients. Technical success was
defined as %30% residual stenosis as seen on the post treatment angiogram. Blood samples for analyses of fasting plasma
values of homocysteine, fibrinogen, D-dimer, activated protein C resistance were drawn upon admission. Median follow-up
for all procedures was 22 months (range 0–55 months). Patency was defined as freedom from R50% restenosis or
reocclusion.
Results. The technical success rate for all procedures was 93%. The 1-year cumulative primary patency rate based on
intention to treat was 85%. Multivariate analysis revealed a significant independent association between patency rates and
levels of fibrinogen and homocysteine and the nature of the lesion treated (stenosis vs. occlusion).
Conclusion. The aetiology of restenoses and reocclusions is probably multifactorial. Procoagulant activity, the nature of the
lesion treated and homocysteine levels within and above the upper range of normal limits are important risk factors for
failure after endovascular treatment of the common iliac arteries.Keywords: Restenosis; Reocclusion; Homocysteine; D-Dimer; Fibrinogen; PTA; Common iliac arteries; Survival analysis.Introduction
Patency rates after percutaneous transluminal angio-
plasty (PTA) for treatment of intermittent claudication
caused by occlusive disease of the common iliac
arteries are reported to be 65% after treatment of
stenoses and 54% after treatment of occlusions at four
years.1,2 The 4-year patency rates of angioplasties for
critical limb ischaemia are lower, 53% after treatment
of stenoses and 44% for occlusions. Iliac stenting
improves patency to 77 and 61% after treatment of
stenoses and occlusions for intermittent claudication,
67 and 53% after treatment of stenoses and occlusions
for critical limb ischaemia after four years.1 Early
failures are attributed to myointimal hyperplasiaing author. Dr E. Laxdal, MD, Department of Vascular
keland University Hospital, Bergen, Norway.
: elin.laxdal@helse-bergen.no
0244 + 07 $35.00/0 q 2005 Elsevier Ltd. All rights resertriggered by the mechanical trauma of angioplasty.3
Later failures are ascribed to the progress of the
atherosclerotic disease.4
Failure after vascular and endovascular surgery is
associated with a variety of factors: young age and
gender,5,6 the severity of ischaemia, the nature of
the lesion treated and run-off.1,7,8 Enhanced procoa-
gulant and inflammatory markers such as elevated
pre-treatment levels of fibrinogen, D-dimer and
activated protein C resistance are associated with
restenosis after angioplasty.9,10,11 Elevated plasma
homocysteine is an independent risk factor for
atherosclerosis,12 though not clearly linked to an
increased risk of recurrence after cardiovascular
intervention.13,14 The results of the nine studies
hitherto published on the association between failure
after peripheral vascular surgery and homocysteine
levels are ambiguous.9,15–22 In our earlier studies, weEur J Vasc Endovasc Surg 31, 244–250 (2006)
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Table 1. Risk factors in 103 patients subjected to endovascular
treatment of 139 common iliac artery stenoses or occlusions
Risk factor %
Heart disease 31
Hypertension, medically treated 30
Diabetes Mellitus 15
COPD 4
Stroke 11
Smoking 71
Se-creatinine O125 mmol/l 6
COPD denotes chronic obstructive pulmonary disease.
Homocysteine and Iliac PTA 245found elevation of D-dimer levels predictive of failure
after endovascular treatment of the above-knee
femoro-popliteal artery,9 and low values of homo-
cysteine predictive of restenosis after carotid
endarterectomy.19
Conditions of flow and shear stress are important
for the development of intima hyperplasia23,24 and risk
of failure may vary depending on the anatomical
localisation of the lesion in the vascular tree as well as
the treatment modality studied. The different physio-
logical properties of the artery (i.e. muscular or elastic)
determine the response to the trauma of endovascular
treatment.25 The variation in the properties of the
endothelial cells may contribute these differences.26 To
avoid confounders, it is of importance to examine the
results of one treatment modality at a well defined
anatomical site.
The aim of the present study is to investigate the
relationship between plasma levels of homocysteine
and other haemostatic and clinical risk factors and
restenosis or reocclusion after endovascular treatment
of symptomatic atherosclerosis of the common iliac
arteries.Patients and Methods
From October 1999 to October 2003, a prospective
study of 197 primary endovascular interventions of
the common iliac arteries in 149 patients done at our
institution was performed. Percutaneous transluminal
angioplasty (PTA) was carried out in 96 cases and
additional stenting in 101 cases.
Technical success was defined as a residual stenosis
!30% on the post-treatment angiogram. In cases with
a doubtful result, intraarterial pressure measurement
proximally and distally to the lesion was used for
clarification.27 A post-treatment pressure gradient !
5 mmHg was accepted as a criterion for success.
Thirteen procedures (nine PTA’s and four stents)
were excluded from the study because of technical
failure. Forty procedures were registered as lost to
follow-up because of missing duplex-ultrasound
examination or angiography to confirm the status of
patency. Ten patients (13 procedures) died early (!6
months after the procedure) in the follow up period
and 18 patients (27 procedures) had either moved too
far away, could not be reached by telephone or post or
refused to participate in the study. Five cases in which
the study blood tests were not taken were likewise
excluded. Thus the study included 139 successful
procedures in 103 patients.
The study group consisted of 79 men (77%) and 24
women (33%) with a mean age of 62 years (range 41–88years). Risk factors are listed in Table 1. The indication
for treatment was intermittent claudication in 112
cases (81%) and critical ischaemia in 27 (19%). Critical
ischaemia was defined according to the second
European Consensus Document on chronic critical
leg ischaemia.28
The quality of run-off was classified into two groups
according to following criteria: group a: patent
superficial femoral, profunda femoris and popliteal
arteries without significant stenoses as well as cases
with runoff into a patent femoro-femoral cross-over
bypass, with or without patent ipsilateral and
contralateral superficial femoral arteries. Group B:
Occluded or stenotic (R50%) superficial femoral
and/or popliteal arteries. The external iliac artery
was patent and without significant stenoses in all
cases.
The mean length of all lesions was 2.2 cm (range
0.5–8 cm). The mean length of occlusions was 4.7 cm
(range 0.5–8 cm). The endovascular technique applied
was as described by Dotter and Judkins.29 PTA with
stenting was routinely applied for treatment of
occlusions. PTA alone was the standard treatment of
stenoses. However, selective stenting was performed if
the result of PTA alone was deemed unsatisfactory due
to residual stenosis, in cases complicated with
dissection (5 cases) or perforation (1 case).
All cases treated with stent were given Heparin
5000 i.u. intravenously during the procedure. If
tolerated, Aspirin 160 mg was prescribed on a daily
basis thereafter. No other platelet-inhibiting medi-
cation was prescribed if Aspirin treatment was contra-
indicated (26 of 139 cases (27%)).
Follow up was routinely performed at 1 and 12
months with ankle-arm pressure measurement and
clinical evaluation. Recurrent symptoms were con-
sidered to be a sign of a significant restenosis or
reocclusion, and status was then confirmed by duplex
ultrasound and angiography. At the end of the study
period, all patients registered alive with a patent
reconstruction were invited to an end of study
examination with ankle-arm pressure measurement
and ultrasound assessment. If symptoms had recurredEur J Vasc Endovasc Surg Vol 31, 3 2006
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reocclusion in the treated segment, the event was
registered at the time of reoccurrence of symptoms.
For patients declining the end of study follow up, data
were censored at the previous follow up when the
status of patency was known.
A duplex ultrasound examination of the distal
abdominal aorta, the iliac and common femoral
arteries was performed by two experienced ultra-
sound technicians. A velocity increase in the common
iliac artery of O2.5 compared to the velocity proxi-
mally to the aortic bifurcation associated with a loss of
reverse flow component in the external iliac artery was
the criterion for a R50% stenosis.30 Patency was
defined as freedom from either reocclusion or R50%
restenosis, both of these criteria being used as end-
points. Median follow-up time for all procedures was
22 months (range 0–55 months).
Blood for analysis of fasting plasma homocysteine
(Hcy) (normal range 0–15 umol/l), fibrinogen (Fibr)
(normal range 2–4 g/l), D-dimer (D dim) (normal
range 0.0–0.5 mg/l), activated protein C resistance,
with exception of patients on oral anticoagulation
(normal value!2) was drawn upon admission.
Calculations of technical success rates are based on
all procedures performed in the study period
(included and excluded procedures). All remaining
calculations and comparisons of patency rates were
based on successfully treated cases.
Comparison of patency rates between groups with
respect to age, sex, risk factors (Table 1), anatomy of
the lesions and run-off, homocysteine and haemostatic
risk factors, treatment with platelet inhibitors, choles-
terol lowering medication, beta-blockers or calcium
receptor antagonists, indication for treatment and the
endovascular technique applied was performed with
univariate analysis (log-rank test).
The values of homocysteine, fibrinogen and
D-dimer were dichotomised by division into tertiles
and quartiles for univariate and multivariate analysis.
High versus low levels were compared in a sequential
manner with respect to events (Table 2). Results with p
values !0.2 were included in a Cox multivariate
analysis. For factors yielding more than one p valueTable 2. Percentiles of measured values of homocysteine, fibrinogen a
log-rank test in a stepwise manner with respect to patency
Study VI. Percentiles—log-rank test
25 p 33 p 50 p 66
8.6 0.09 8.8 0.14 10 0.35 11.8
3.3 0.22 3.5 0.048 3.7 0.23 4.1
0.26 0.27 0.29 0.84 0.4 0.13 0.57
* N.V. Normal value
Eur J Vasc Endovasc Surg Vol 31, 3 2006!0.2 on log-rank test, only the percentile of the lowest
p value was included in the multivariate analysis. All
data were prospectively registered in a vascular
registry run by the department and analysed with
SPSS 11.0 for Windows. Statistical significance was
accepted at p!0.05.Results
The technical success rate for all procedures (included
and excluded) was 93% (Fig. 1), 96% for stenting and
91% for PTA. The 30 days mortality after the
procedures was nil. Procedure-related complications
are listed in Table 3. Only three cases with critical
ischaemia resulted in amputation. All three cases had
severe distal disease preventing limb salvage and were
amputated despite a patent iliac reconstruction.
The 1-year cumulative primary patency rate for all
procedures (included and excluded) was 85% (Fig. 1).
The 1-year primary patency rate was 89% for stenoses
and 71% for occlusions. The 12 and 18 months patency
rates after treatment with kissing stents were 68 and
61%, respectively.
Univariate analysis showed significantly inferior
patency rates in arteries treated for occlusions as
compared to stenoses (pZ0.009) (Fig. 2). Patency was
also significantly inferior after treatment with kissing
stents (pZ0.005) (Fig. 3), for homocysteine values
above the 75 percentile (O13.36 mmol/l) (pZ0.045)
(Fig. 4) and plasma fibrinogen values above the upper
tertile (O3.5 g/l) (pZ0.047) (Fig. 5; Table 2).
On multivariate analysis, treatment for occlusions
(pZ0.005), values of plasma homocysteine O
13.36 mmol/l (highest quartile) (pZ0.005) and serum
fibrinogen O3.5 g/l (upper 66%) (pZ0.047) were
independent predictors of failure (Table 4). D-dimer
levels, Activated protein C resistance, clinical risk
factors (Table 1), degree of ischaemia, length of the
reconstruction, runoff, medical treatment and inter-
ventions with PTA only (without stent) were not
significantly associated with failure.nd D-dimer were used for division into groups for comparison with
p 75 p N.V.* p
0.64 13.36 0.045 %15 0.4 Hcy mmol/l %
0.8 4.3 0.83 %4 0.64 Fibr g/l%
0.49 0.71 0.58 %0.5 0.36 D-dim mg/l %
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Fig. 1. Patency rates of 197 common iliac endovascular
interventions in 149 patients. Calculation is based on all
cases treated in the study period (cases included as well as
excluded from the study). Patency is defined as an open
artery without R50% restenosis. The numbers under the
curve display patients at risk.
Months
24211815129630
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1
0.0
 105 102        100         93         78         74         62         56   Stenoses
   25         25          22          19         15        13          10           6    Occlusions
Stenoses
Occlusions
p = 0.009
Patency
Fig. 2. Comparison of patency rates of 139 common iliac
endovascular procedures in patients with occlusions (broken
line) and stenoses (unbroken line). The numbers under the
curve indicate patients at risk.
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The technical success rate of 93% and 1-year primary
patency rate of 89% after treatment of stenoses and
71% for occlusions in the present series are acceptable
and comparable to those reported by others.1,2
However, the 1-year patency rates after treatment
with kissing stents in our series are lower than
previously reported, probably due to the high number
of occlusion treated with this technique.31 The
technical success rate was better in the stented group
as compared to PTA alone. The risk of complications
was not increased in the groups treated with
additional stenting. Only one reocclusion demanded
surgery (aorto-bifemoral bypass). All other cases
suffering symptoms demanding reintervention were
treated successfully with endovascular techniques.
The fact that the technical success was determined
on the basis of completion angiography only and not
duplex ultrasound may be regarded as a limit to the
validity of the study, since residual stenoses may be
difficult to detect on angiograms. However, the
reliability of duplex ultrasound is also debateable for
reasons of operator dependency and a sensitivity of
80% and specificity of 95% in detecting 50% stenosis.32Table 3. Procedure-related complications to 139 common iliac
endovascular procedures in 103 patients
Complication n Treatment n
Distal embolisation 1 Aspiration 1
Dissection 5 Stent 5
Haematoma 4 Conservative 4
Bleeding 1 Operation 1
Perforation 1 Covered stent 1The patency rate following treatment of occlusions
was significantly worse than after treatment of
stenoses, which is consistent with earlier reports of
endovascular treatment of iliac as well as superficial
femoral arteries.1,2,9 This may be due to an increased
thrombogenicity secondary to a greater arterial trauma
needed for a satisfactory result.
The relationship between elevated homocysteine
and atherosclerosis was first observed by McCully in
patients with homocysteinuria, a metabolic deficiency
resulting from an autosomal recessive error.33 Mild
hyperhomocysteinemia can be caused by deficiency of
vitamin B12, B6 and Folate, various life style factors as
well as age,34 and is a predictor of cardiovascular and
all cause mortality in a dose dependent fashion.35
The results of observational studies on the relation-
ship between failure after coronary bypass orMonths
24211815129630
.1
0.0
p=0.0005
       32          30         27          21          17          17         12            5   Kissing stents
Fig. 3. Comparison of patency rates after endovascular
treatment of symptomatic atherosclerotic lesions in common
iliac arteries with stent: with kissing technique (broken line)
and without kissing technique (unbroken line). The numbers
under the curve indicate patients at risk.
Eur J Vasc Endovasc Surg Vol 31, 3 2006
Patency
Months
24211815129630
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1
0.0
  96           95            92           87            73           67           56           47 Homocysteine ≤13.36 µmol/l
     31           28            28           23            18           17           14           13 Homocysteine >13.36 µmol/l
Fig. 4. Comparison of homocysteine values with respect to
patency rates after endovascular treatment of symptomatic
occlusive disease in the common iliac arteries: The upper
25% (O13.36 mmol/l) (broken line) compared with the lower
75% (%13.36 mmol/l) (unbroken line) of measured values.
The numbers displayed under the curve signify patients at
risk.
E. Laxdal et al.248interventions and homocysteine levels have so far
been ambiguous.13,14 The results of retrospective as
well as prospective observational studies on periph-
eral vascular and endovascular surgery are no less
conflicting. An association between hyperhomocystei-
nemia and failure was not proven in seven of the nine
studies hitherto published.9,15–22 Two of these studies
are based on a case mix of treatment in different
anatomical locations performed with a variety of
techniques.18,22 Three other studies are based on
results after infrainguinal bypass surgery, either withMonths
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Fig. 5. Comparison of patency rates after 139 common iliac
endovascular interventions in patients with fibrinogen O3.5
and %3.5 g/l. The numbers under the curve indicate
patients at risk.
Table 4. Multivariate analysis (Cox’ proportional hazard model) of ris
associated with patency rates in 139 iliac artery endovascular recons
Variables b Standard error
Occlusion vs. stenosis 0.983 0.350
HcyO13.36 mmol/l 0.879 0.332
FibrinogenO3.5 g/l 0.660 0.327
Eur J Vasc Endovasc Surg Vol 31, 3 2006a mix of prosthetic bypass and vein or vein bypass
above and below the knee.15–17 Only four studies are
prospective and of one treatment modality performed
in a well defined arterial segment.9,19–21
In two earlier studies performed in our group,
hyperhomocysteinemia was not a predictor of failure
after endovascular treatment of the above-knee
femoro-popliteal artery, and low homocysteine levels
were predictors of restenosis after carotid endarter-
ectomy.9,19 In the latter study the numbers included
were low and events few, rendering the probability of
a type 1 error likely. In the present study, homocysteine
levels in the upper quartile (O13.36 mmol/l) were
independent predictive of failure. These conflicting
results may be explained by anatomically determined
differences in arterial susceptibility to homocysteine.
This view is consistent with the findings of the Hoorn
study of an association between hyperhomocysteine-
mia and risk for aortoiliac but not isolated crural
occlusive disease36 and the lack of association between
the progression of carotid disease and elevated
homocysteine in another study.12 Furthermore, the
mean follow-up time of our studies is relatively short,
and thus we are likely detecting intimal hyperplasia
not progressive atherosclerosis.
The increased risk of restenosis in patients with
fibrinogen levels O3.5 g/l in the present study is
consistent with a previous report, and may reflect an
increased procoagulant or inflammatory activity in
patients.37 Assuming that increased procoagulant status
plays a role in the pathogenesis of restenosis, pre-and
post-procedural fibrinogen levels may be predictive of
failure. The results of studies on the subject have so far
been conflicting. In one study of 27 renal angioplasties,
fibrinogen levels were significantly associated with
failure,38 but only two offour major studies on restenosis
after coronary angioplasty found fibrinogen predictive
of failure.39–42 Reviewing studies on the association
between fibrinogen levels and failure after peripheral
arterial intervention the results appear to be no less
conflicting. However, when grouping the studies
according to the localisation of the treatment in the
arterial tree, a clearer picture emerges: Of three
prospective studies of endovascular intervention,
based on a case mix (anatomical localisation not
defined), failure had no association with fibrinogen
levels in one, low levels were predictor of failure ink factors demonstrated with univariate analysis to be significantly
tructions
p value Hazard ratio 95% CI
0.005 2.671 1.344–5.307
0.007 1.935 1.269–4.569
0.047 1.935 1.010–3.707
Homocysteine and Iliac PTA 249another and high levels in the third.43–45 Four prospec-
tive studies on results after interventions in the femoro-
popliteal segment demonstrate that fibrinogen levels are
not predictive of failure.9,46–48 Whereas two studies, the
present included, on results of intervention in the iliac
artery both find fibrinogen levels predictive of failure in
this segment.10
The aforementioned studies support the view that
there may be regional biological differences in the
arterial tree that explain the variation in reaction to
intervention as well as treatment results. This view is
further supported by Schillinger et al., who investi-
gated the inflammatory response after endovascular
stenting and found higher values of CRP and
fibrinogen after treatment of the femoro-popliteal
artery than the iliac artery.25 Even if fibrinogen levels
are not predictive of failure after femoro-popliteal
PTA, they are associated with the severity of lower
limb ischaemia, with higher values in patients with
critical limb ischaemia (p!0.05).
The number of studies on the association between
D-dimer levels and the risk of failure after endovas-
cular intervention are scarce. One study of coronary
endovascular intervention compared patients with
myocardial infarction (MI) and patients with stable
coronary disease (SCD). The MI patients had signifi-
cantly higher D-dimer levels than the patients in the
SCD group, the elevation of D-dimer being a
significant predictor for restenoses in the MI group.49
In a previous study we found that elevated pre-
treatment level of D-dimer was a significant predictor
of failure after endovascular treatment of the above-
knee femoro-popliteal artery9 but not after carotid
endarterectomy.19
Our findings suggest an increased procoagulant
activity, either primary or secondary to inflammation,
is a predictor of endovascular treatment failure in the
above-knee femoro-popliteal artery (D-dimer) and the
common iliac artery (fibrinogen), but not after carotid
surgery. The aetiology of restenoses and reocclusions
after endovascular intervention in the common iliac
artery is probably multifactorial. Factors enhancing
the activity of the fibrinolytic system, the nature of the
lesion treated and homocysteine levels above the
upper range of normal are important risk factors for
failure after endovascular treatment of the common
iliac arteries.References
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